Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 29, 2016Journal of Clinical Oncology

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPhilippe ArmandBoston UniversityMSMargaret A. ShippBroad InstituteVRVincent RibragInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Armand et al. (2016) studied this question.

synapsesocial.com/papers/69dab5cd8988aeabbe687838https://doi.org/10.1200/jco.2016.67.3467
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012 · 12,860 citations
  2. 2PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma2014 · 3,599 citations
  3. 3Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma2010 · 18 citations
  4. 4Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer2015 · 6,324 citations
  5. 5Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial2013 · 440 citations